Sodium Methoxide → HCID 86597448, compound

HRID 713722Notes

Reaction equation

HRID 713722 reaction equation
C([O:9][C@@H:10]1[C@H:14]([O:15]C(=O)C2C=CC=CC=2)[C@@H:13]([CH2:24][O:25]C(=O)C2C=CC=CC=2)[O:12][C@H:11]1[N:34]1[C:38]2=[CH:39][N:40]=[N:41][C:42](=[O:43])[C:37]2=[N:36][CH2:35]1)(=O)C1C=CC=CC=1.C[O-].[Na+]>CO>[C@@H:11]1([N:34]2[C:38]3=[CH:39][N:40]=[N:41][C:42](=[O:43])[C:37]3=[N:36][CH2:35]2)[O:12][C@H:13]([CH2:24][OH:25])[C@@H:14]([OH:15])[C@H:10]1[OH:9]

Participants

4

Conditions

Temperature
20 °C

Procedure

1-(2,3,5-tri-O-Benzoyl-β-D-ribofuranosyl)imidazo[4,5-d]pyridazin-4-one (555 mg, 0.9 mmol) was added to a solution of sodium methylate (205 mg) in methanol (25 mL) and stirred at 20° C. for 2 hours. The reaction mixture was evaporated to dryness. The residue was dissolved in water and washed with ethyl acetate. The aqueous layer was concentrated under pressure. The crude product was purified on silica gel reverse-phase (C18) using water as eluant to give the title compound (220 mg) as a white powder.

Workup

  1. customThe reaction mixture was evaporated to dryness
  2. dissolutionThe residue was dissolved in water
  3. washwashed with ethyl acetate
  4. concentrationThe aqueous layer was concentrated under pressure
  5. customThe crude product was purified on silica gel reverse-phase (C18)

Sources & evidence

ORD record
ord-095636659df94931860b56da8286aa4c
Source dataset
uspto-grants-2015_11
Patent number
US09186369B2

Reaction notes

Loading…